RPE65 and inherited retinal dystrophy: In the study by Albert M. Maguire et al. (2021) [15], which involved 29 patients with RPE65 mutation-associated inherited retinal dystrophy (IRD), gene augmentation therapy was administered using the recombinant adeno-associated viral vector Voretigene Neparvovec.